MRSA new treatments on the horizon: Current status

Injury

Volumn 42, Issue SUPPL. 5, 2011, Pages

  Wilcox, M H ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Ceftaroline; Dalbavancin; Oritavancin; Telavancin

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; BC 3781; CEFTAROLINE; CEFTOBIPROLE; CLINDAMYCIN; COTRIMOXAZOLE; DALBAVANCIN; DAPTOMYCIN; FLUCLOXACILLIN; FUSIDIC ACID; ICLAPRIM; LINEZOLID; ORITAVANCIN; PLEUROMUTILIN; RETAPAMULIN; RIFAMPICIN; TELAVANCIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BONE INFECTION; CATHETER INFECTION; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG SAFETY; FOLLOW UP; HUMAN; INFECTIOUS ARTHRITIS; INJURY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OSTEOMYELITIS; PRIORITY JOURNAL; PROSTHESIS MATERIAL; SKIN INFECTION; TREATMENT FAILURE; TREATMENT PLANNING;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GLYCOPEPTIDES; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; TEICOPLANIN;

EID: 84555195514     PISSN: 00201383     EISSN: 18790267     Source Type: Journal    
DOI: 10.1016/S0020-1383(11)70132-2     Document Type: Article

References (27)

1. SE Cosgrove, G Sakoulas, EN Perencevich, MJ Schwaber, AW Karchmer, Y Carmeli Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis Clin Infect Dis 36 2003 53 59 (Pubitemid 36099097)
2. AL Graziani, LA Lawson, GA Gibson, MA Steinberg, RR MacGregor Vancomycin concentrations in infected and non-infected human bone Antimicrob Agents Chemother 32 1988 1320 1322
3. B Périchon, P Courvalin VanA-type vancomycin-resistant Staphylococcus aureus Antimicrob Agents Chemother 53 2009 4580 4587
4. LK Hidayat, DI Hsu, R Quist, KA Shriner, A Wong-Beringer High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity Arch Intern Med 166 2006 2138 2144 (Pubitemid 44631403)
5. TP Lodise, J Graves, A Evans, E Graffunder, M Helmecke, BM Lomaestro et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin Antimicrob Agents Chemother 52 2008 3315 3320
6. A Soriano, F Marco, JA Martínez, E Pisos, M Almela, VP Dimova et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia Clin Infect Dis 46 2008 193 200 (Pubitemid 351269157)
7. MJ Rybak, BM Lomaestro, JC Rotschafer, RC Moellering, WA Craig, M Billeter et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
8. GM Rossolini, E Mantengoli, F Montagnani, S Pollini Epidemiology and clinical relevance of microbial resistance determinants versus anti-Gram-positive agents Curr Opin Microbiol 13 2010 582 588
9. M Sánchez García, MA De la Torre, G Morales, B Peláez, MJ Tolón, S Domingo et al. Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit JAMA 303 2010 2260 2264
10. J Perlroth, M Kuo, J Tan, AS Bayer, LG Miller Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections: a systematic review of the literature Arch Intern Med 168 2008 805 819 (Pubitemid 351620083)
11. HM Nguyen, CJ Graber Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer? J Antimicrob Chemother 65 2010 24 36
12. M Lefebvre, C Jacqueline, G Amador, V Le Mabecque, A Miegeville, G Potel et al. Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis Int J Antimicrob Agents 36 2010 542 544
13. W Zimmerli, AF Widmer, M Blatter, R Frei, PE Ochsner Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group JAMA 279 1998 1537 1541 (Pubitemid 28233008)
14. J Burnie, R Matthews, A Jiman-Fatami, P Gottardello, S Hodgetts, S D'arcy Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin Clin Infect Dis 31 2000 684 689 (Pubitemid 32295487)
15. GR Corey, M Wilcox, GH Talbot, HD Friedland, T Baculik, GW Witherell et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection Clin Infect Dis 51 2010 641 650
16. HK Sun, K Duchin, CH Nightingale, JP Shaw, J Seroogy, DP Nicolau Tissue penetration of telavancin after intravenous administration in healthy subjects Antimicrob Agents Chemother 50 2006 788 790 (Pubitemid 43191003)
17. RE Mendes, HS Sader, RN Jones Activity of telavancin and comparator antimicrobial agents tested against Staphylococcus spp. isolated from hospitalised patients in Europe (2007-2008) Int J Antimicrob Agents 36 2010 374 379
18. AP MacGowan, AR Noel, S Tomaselli, HC Elliott, KE Bowker Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection Antimicrob Agents Chemother 55 2011 867 873
19. A Belley, GA McKay, FF Arhin, I Sarmiento, S Beaulieu, I Fadhil et al. Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing Antimicrob Agents Chemother 54 2010 5369 5371
20. CM Rubino, SA Van Wart, SM Bhavnani, PG Ambrose, JS McCollam, A Forrest Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia Antimicrob Agents Chemother 53 2009 4422 4428
21. GG Zhanel, D Calic, F Schweizer, S Zelenitsky, H Adam, PR Lagacé-Wiens et al. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin Drugs 70 2010 859 886
22. R Novak, DM Shlaes The pleuromutilin antibiotics: a new class for human use Curr Opin Investig Drugs 11 2010 182 191
23. H Boucher, LG Miller, RR Razonable Serious infections caused by methicillin-resistant Staphylococcus aureus Clin Infect Dis 51 Suppl 2 2010 S183 S197
24. T Lalani, HW Boucher, SE Cosgrove, VG Fowler, ZA Kanafani, GA Vigliani et al. S. aureus Endocarditis and Bacteraemia Study Group. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia J Antimicrob Chemother 61 2008 177 182
25. PJ Harwood, C Talbot, M Dimoutsos, G Sunderland, D Shaw, MH Wilcox et al. Early experience with linezolid for infections in orthopaedics Injury 37 2006 818 826 (Pubitemid 44223490)
26. A Papadopoulos, D Plachouras, E Giannitsioti, G Poulakou, H Giamarellou, K Kanellakopoulou Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study J Chemother 21 2009 165 169
27. ME Falagas, II Siempos, KZ Vardakas Linezolid versus glycopeptide or betalactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials Lancet Infect Dis 8 2008 53 66 (Pubitemid 351620940)